CYCLosporinE A in Reperfused Acute Myocardial Infarction
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Infarct size is a major determinant of prognosis after myocardial infarction (MI). It has
been reported that Cyclosporine A (CsA) administered immediately prior to percutaneous
coronary intervention (PCI) significantly could reduce reperfusion injury and consequently
infarct size in ST elevation MI (STEMI) patients.
CYCLE trial is a multicenter, controlled, randomized open label study, with blind assessment
of endpoint measures. The objective is to determine whether a single i.v. dose of CsA within
6 hour onset of symptoms of STEMI in 444 patients, improves outcomes after successful primary
PCI, by reducing myocardial injury associated to reperfusion.
Phase:
Phase 3
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research